Lead Product(s) : DNL747
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Denali Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis
Details : DNL747 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Amyotrophic Lateral Sclerosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 28, 2018
Lead Product(s) : DNL747
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Denali Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate DNL747 in Subjects With Alzheimer's Disease
Details : DNL747 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 28, 2018
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
